In the effort to prevent contrast-induced acute kidney injury (CI-AKI), several pharmacologic agents have been tested for their single or combined nephroprotective properties. To date, however, no drug has been officially approved for this aim. This article focuses on the three agents that have been most extensively studied: statins, N-acetylcysteine, and ascorbic acid. Particular attention is paid to the impact of these drugs on the CI-AKI prevention and improved prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.iccl.2014.03.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!